Northern Trust’s Oramed Pharmaceuticals ORMP Stock Holding History

Northern Trust’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,569	Closed	-$41.4K	–	4509
2023 Q2	$41.4K	Hold	11,569	–	–	﹤0.01%	4260
2023 Q1	$25.2K	Sell	11,569 -263	-2%	-$835	﹤0.01%	4406
2022 Q4	$142K	Sell	11,832 -2,093	-15%	-$16.3K	﹤0.01%	3991
2022 Q3	$90K	Buy	13,925 +285	+2%	+$2.31K	﹤0.01%	4144
2022 Q2	$62K	Sell	13,640 -268,738	-95%	-$1.44M	﹤0.01%	4342
2022 Q1	$2.44M	Buy	282,378 +39,253	+16%	+$402K	﹤0.01%	3000
2021 Q4	$3.47M	Buy	243,125 +17,294	+8%	+$362K	﹤0.01%	2924
2021 Q3	$4.96M	Buy	225,831 +14,749	+7%	+$251K	﹤0.01%	2734
2021 Q2	$2.82M	Buy	+211,082	New	+$2.41M	﹤0.01%	3187
2019 Q1	–	Sell	-18,269	Closed	-$55K	–	4254
2018 Q4	$55K	Buy	18,269 +259	+1%	+$1.07K	﹤0.01%	4034
2018 Q3	$88K	Buy	+18,010	New	+$93.5K	﹤0.01%	4051

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust's ORMP Position: Q3 2023 in Review

Northern Trust sold out of Oramed Pharmaceuticals (ORMP) in Q3 2023, closing a stake of 11,569 shares — an estimated $41.4K sold.

Northern Trust first reported a position in ORMP in Q3 2018 and held it in 11 quarters. The position peaked at $4.96M in Q3 2021. 56 funds tracked by Wall St. Rank hold ORMP as of Q3 2023.

Northern Trust reported no remaining Oramed Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Northern Trust sold 11,569 Oramed Pharmaceuticals shares in Q3 2023, an estimated $41.4K.
Northern Trust first reported a position in Oramed Pharmaceuticals in Q3 2018 and held it in 11 quarters.
Northern Trust's Oramed Pharmaceuticals position peaked at $4.96M in Q3 2021.
56 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2023.

Based on Northern Trust's 13F filing for Q3 2023, filed 13 Nov 2023.